- No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
REGN
NASDAQ
Week ended 24 Jul 2026
Weekly Investor Report
Regeneron Pharmaceuticals Inc · Healthcare · Biotechnology
Latest close
656.0 USD
-3.1%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is -8.1% below the Trend Line and sits at 41.9% of its 52-week range. The latest completed week returned -3.1%, after a 3.7% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive. Options positioning is bullish with 40/100 conviction, while the latest news-sentiment score is 47/100. Near-term considerations: volume confirmation is below normal; earnings are due in 0d.
Setup score
37
out of 100
Latest Close
656.0 USD
24 Jul 2026
1W Return
-3.1%
latest completed week
4W Return
3.7%
short-term follow-through
12W Return
-6.3%
quarterly tape
Trend Breadth
55.8%
29 of 52 weeks active
Volume Ratio
0.8x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-3.1%
Latest completed week; four-week move 3.7%.
Indicator stack
31/41
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Options pressure
Bullish
40/100 conviction; expected move 8.4%.
News sentiment
47/100
62 relevant articles in the latest sentiment read.
Event risk
0d
Next report is scheduled for 30 Jul 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -8.1% below the Trend Line and sits at 41.9% of its 52-week range. The latest completed week returned -3.1%, after a 3.7% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
30 Jan
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.1312-week average 0.22
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.13Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 3.7% over four weeks, -6.3% over 12 weeks, and 17.1% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year29
Trend breadth55.8%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.69Latest activity-pressure read.
Pressure change38.5%Four-week change in activity pressure.
Leadership-11.92Latest relative-leadership reading.
RS change33.7%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive.
Factor week 26 Jul 2026
Financial statements through 31 Dec 2025
Field coverage 100%
Model confidence 96%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength88/100Blend of value, momentum, and quality. Underlying universe rank 13; rank 1 is best.
Value69/100Relative valuation strength. Underlying universe rank 32; rank 1 is best.
Quality89/100Profitability and accounting quality. Underlying universe rank 12; rank 1 is best.
Momentum67/100Medium-term price momentum. Underlying universe rank 34; rank 1 is best.
Growth20/100Revenue and earnings growth. Underlying universe rank 81; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework68/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 15.5x Price divided by trailing earnings.
- Price / sales
- 4.6x Market value relative to trailing revenue.
- EV / EBITDA
- 11.9x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 8.6% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 84.5% Gross profit retained from each unit of revenue.
- Operating margin
- 34.9% Operating profit retained from revenue.
- Free-cash-flow margin
- 39.3% Free cash flow generated from revenue.
- Return on invested capital
- 14.3% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 5.9% Latest one-year revenue growth.
- EPS growth
- -1.7% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- 20.1% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 5/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 0.6% Cash dividends relative to market value.
- Buyback yield
- 4.4% Net share repurchases relative to market value.
- Shareholder yield
- 5.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- -0.0x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningBullish
REGN shows bullish options pressure with a 40/100 conviction score, put-call volume ratio of 0.65, expected move of 8.4%, and Sharemaestro trend signal inactive.
Conviction40/100
Expected move8.4%
Put/call volume0.65
Insider activity0 / 20
0 acquisitions and 20 disposals in the latest 180-day insider tape.
Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.News sentiment47/100
Weighted news tone is neutral across 62 relevant articles.
13 positive · 33 neutral · 16 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings0dNext report is scheduled for 30 Jul 2026; event risk rises as the date approaches.
Options expected move8.4%Nearest-chain priced movement where available.
52-week drawdown-19.9%Distance below the 52-week high.
13-week volatility3.8%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
30 Jan
27 Feb
27 Mar
24 Apr
22 May
19 Jun
24 Jul
Weeks higher13 of 2613 weeks finished lower.
Best week+5.9%Week of 6 Feb.
Worst week-8.4%Week of 22 May.
Latest week-3.1%Week of 24 Jul.
Shape of recent returns
Strong gains1
Modest gains12
Flat weeks0
Modest losses11
Sharp losses2
Recent vol3.8%13-week weekly-return volatility.
Base vol4.1%52-week weekly-return volatility.
Up/down split29/23Count of positive and negative weeks in the 52-week window.
Average skew3.3% / -3.2%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank33 / 100
Group average1.3%
Trend breadth51.0%
Trend51.0%active weekly trend signals
MD75.0%positive activity pressure
RS48.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank31 / 100
Group average0.5%
Trend breadth67.0%
Trend67.0%active weekly trend signals
MD72.0%positive activity pressure
RS65.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape35/100
Trend, activity pressure, participation, and risk combine to a 35/100 tape read.
Indicator analysis11/100Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.
Activity pressure 0.13; No reversal markers Factors78/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 13 SVQF68/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 235.0 of 726 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options56/100REGN shows bullish options pressure with a 40/100 conviction score, put-call volume ratio of 0.65, expected move of 8.4%, and Sharemaestro trend signal inactive.
Bullish · Call-side pressure · Expected move 8.4% Sentiment47/100Weighted news tone is neutral across 62 relevant articles.
REGN Shareholder Alert: September 14, 2026 Lead Plaintiff Deadline in Regeneron Pharmaceuticals, Inc. Securities Class Action - Contact The Gross Law Firm Insiders0 / 200 acquisitions and 20 disposals in the latest 180-day insider tape.
Earnings0dNext report is scheduled for 30 Jul 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 24 Jul 2026 | 656.0 USD | -3.1% | 714.1 USD | 778.4 USD | -0.69 | -11.92 | 3.9M | Off |
| 17 Jul 2026 | 676.7 USD | 1.8% | 718.3 USD | 778.9 USD | -0.80 | -10.64 | 3.0M | Off |
| 10 Jul 2026 | 664.5 USD | 1.6% | 721.3 USD | 779.3 USD | -0.94 | -15.89 | 3.6M | Off |
| 3 Jul 2026 | 654.3 USD | 3.4% | 723.8 USD | 779.6 USD | -1.05 | -15.84 | 3.8M | Off |
| 26 Jun 2026 | 632.9 USD | 3.8% | 725.8 USD | 779.8 USD | -1.13 | -17.98 | 5.6M | Off |
| 19 Jun 2026 | 609.9 USD | -0.4% | 730.7 USD | 780.3 USD | -1.18 | -24.59 | 5.7M | Off |
| 12 Jun 2026 | 612.1 USD | -3.7% | 735.5 USD | 781.4 USD | -1.17 | -22.49 | 4.9M | Off |
| 5 Jun 2026 | 635.5 USD | 3.4% | 738.1 USD | 782.4 USD | -1.13 | -17.90 | 5.1M | Off |
| 29 May 2026 | 614.8 USD | -3.8% | 738.7 USD | 783.1 USD | -1.12 | -24.18 | 6.2M | Off |
| 22 May 2026 | 638.9 USD | -8.4% | 739.9 USD | 783.8 USD | -1.09 | -19.09 | 7.7M | Off |
| 15 May 2026 | 697.2 USD | -2.3% | 737.8 USD | 784.4 USD | -0.86 | -11.03 | 4.4M | Off |
| 8 May 2026 | 713.9 USD | 1.9% | 733.7 USD | 784.7 USD | -0.84 | -9.45 | 3.3M | Off |
| 1 May 2026 | 700.4 USD | -6.7% | 728.7 USD | 784.9 USD | -0.79 | -6.39 | 4.8M | On |
| 24 Apr 2026 | 750.5 USD | 0.1% | 725.3 USD | 785.2 USD | -0.74 | 1.51 | 3.8M | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.